

INNOVATIVE IMMUNOTHERAPY DRUG CANDIDATES




Find your partner in pioneering therapeutic solutions

Immunoservice GmbH has welltolerated proprietary **Interleukin-2**-based immunotherapy drug candidates in GMPquality. They are designed to overcome immune exhaustion in areas of high unmet medical need. We have **top clinical expertise** in local application, in particularin **inhalation** to eradicate respiratory tumours.


Based on clinical data an **Orphan Designation** forinhalation treatment ofrenal cell carcinoma was granted to Immunoservice by the EMA. **Committed to animal health?** We have clinically tested drug candidates, too! **Our drug candidates have game changer potential in a variety ofimmune-related indications.**

Oncology

Lung tumours from kidney cancer, melanoma, breast cancer before and after treatment with inhaled IL-2 drug



Instillation in
bladder cancer



Obesity

Patent-protected
immunotherapy



Neurology

ALS / MND, Alzheimer Disease,
Parkinson Disease, Pain



Virology / Skin tumours

Humans and Animals: Local therapy of virusesand
tumours (BPV, HPV, basal cell carcinoma)
before and after treatment with local injection of
our IL-2 drug candidate



We want these urgently needed treatments be available
to human and animal patients as soon as possible!

www.immunoservice.com

About us

Well tolerated innovative immunotherapy - biologicals - We are looking for partners for final MA activities

Immunservice has **particularly well tolerated innovative proprietary Interleukin-2 based drug candidates in GMP quality** for areas of high unmet need, particularly in the fields of:

- 1) oncology
- 2) weight loss/metabolic control
- 3) virology
- 4) neurology
- 5) pain management
- 6) animal health

Overcome immune exhaustion / immune senescence

Our drug candidates are very well tolerated and have shown a significant potential to **overcome immune exhaustion and immune senescence**, offering the chance to strengthen and restore immune functions, induce tumour regression, act antiviral, and counteract neuroinflammation in neurologic deficiencies.

Top expertise in local and in particular inhalation application

Local application such as inhalation of our interleukin-2 based drug candidates reveals exciting potential to control respiratory tumours. Immunservice is an expert in local immune modulation and has the largest clinical experience in patients using inhalation / respiratory application of interleukin-2 based therapies. Inhalation of interleukin-2 induces **complete and partial responses**, allowing long-term control of tumours in the respiratory tract in diseases of high need, e.g. renal cell carcinoma, melanoma, primary lung cancer and other lung metastases, targeting both block buster and orphan markets. An **Orphan Designation for inhalation use in renal cell cancer was granted to Immunservice by the EMA.**

Entering clinical trials

Immunservice has developed **superior Interleukin-2 based drug candidates in GMP quality** for specialized forms of applications such as **topical, mucosal, respiratory and inhalation application**. Innovative drug candidates with specially designed qualities for the local application of Interleukin-2 are critical to achieve **excellent treatment success** alongside the **best possible tolerability**. Our drug candidates are **ready to be employed in phase I and II clinical trials.**


Game changer potential, particularly for high unmet need

Interleukin-2 based therapies also have an impressive potential beyond oncology. There is evidence that they will be **game changers in virology, neurology, weight loss and other metabolic diseases, and pain management**. We would like to discuss these and further potentials (e.g. use in treatment of amyotrophic lateral sclerosis or Parkinson disease, or in animal health) with you. Immunservice is looking for cooperation partners to promote **our clinical developments, in particular the promising respiratory / inhalation application**. Inhaled interleukin-2 enables excellent quality of life and significant long-term control of tumours in the respiratory tract/lung in the high need patient population.




We want these urgently needed treatments be available to human and animal patients as soon as possible!

www.immunservice.com




Before treatment



After 9 months treatment

Patient X001. **Significant partial response** achieved mainly by Interleukin-2 inhalation therapy.



Complete response in the lung after operation of residual metastases


Patient X001. **Complete response.** Removal of all residual metastases was possible due to excellent response to Interleukin-2 inhalation therapy.



Before treatment

After 12 months treatment

Patient X003. CT scan before and after 12 months of mainly inhalation interleukin-2 therapy



Complete response of a huge virus infected tumour area at 6 months after start of local immunotherapy with our drug candidate in a horse with papilloma virus induced tumors (Sarcoids).



We want these urgently needed treatments be available to human and animal patients as soon as possible!
www.immunservice.com

About us

Are you committed to animal health?

Our drug candidates are promising in animal health: against viral infection and against tumors in dogs, cats, horses, and more..... This is an example of a successful „one health“ development approach for animals resulting from human therapy candidates. Field studies with our drug candidates indicate **antiviral activity** and **tumour responses**, exhibiting its potential to **overcome immune exhaustion and immune senescence**.

Learn more about the very promising prospects in this area! **Limited market classification is granted and the potential benefit of the availability of the product on the market has been confirmed by EMA.**

Contact

Feel free to contact us to **initiate co-development and/or partnership**. We are happy to tailor our exciting immunotherapy products to **meet your needs and expectations**. They are ready for human and animal patients in high need! We look for partners who aim for a real **win-win scenario**.

We look forward to talk to you!



Immunservice GmbH

Christoph Probst Weg 4
20251 Hamburg /Germany

E-mail: huland@immunservice.com

Phone: +49 40 61135184

Internet: immunservice.com/en/

Prof. Dr. Dr. Edith Huland

CEO / Managing Director



We want these urgently needed treatments be available to human and animal patients as soon as possible!

www.immunservice.com